Interchangeability of biosimilars - yes or no?

• At: PSWC, Melbourne (Australia) (2014)
• Type: Presentation
• By: ROGER, Simon (Renal Research, Gosford, Australia)
• Abstract:

  The advent of biosimilars has followed the expiration of patents covering biopharmaceuticals, providing opportunities for pharmaceutical companies to develop, produce and market these biosimilars or follow-on biologicals. Switching patients from one product to a similar but [quotright]not quite identical[quotrightB]product may have important

  ..

The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login